Physician profile
Robert W Dean
NPI 1053427815
$13,239.89
in general payments reported to CMS, 2019-2025
46 companies · $2,056 in 2025
The $2,056 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $908 · 2021: $2,597 · 2022: $1,817 · 2023: $1,865 · 2024: $2,158 · 2025: $2,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,079.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,744.70 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Pfizer INC. | $1,291.77 | 2019-2025 | |
| Novo Nordisk INC | $1,273.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,030.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $990.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $868.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $551.85 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $509.44 | 2019-2025 | Eliquis |
| Abbvie INC. | $491.90 | 2021-2024 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.84 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $361.70 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.67 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $353.21 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $342.17 | 2019-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $315.37 | 2019-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $234.47 | 2022-2025 | |
| Esperion Therapeutics, INC. | $207.16 | 2020-2021 | |
| Exact Sciences Corporation | $180.14 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $179.46 | 2019-2022 | |
| Antares Pharma, INC. | $175.97 | 2019-2022 | |
| Lundbeck LLC | $124.07 | 2024-2025 | Rexulti |
| Abbott Laboratories | $118.06 | 2020-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $110.75 | 2024-2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $97.55 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $87.77 | 2021 | |
| Astellas Pharma US INC | $84.37 | 2019-2024 | Veozah, Myrbetriq |
| Eisai INC. | $78.77 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.77 | 2022 | |
| Corium, LLC | $66.23 | 2023-2024 | Azstarys |
| Genentech USA, INC. | $59.79 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $56.53 | 2024-2025 | Rexulti |
| Allergan, INC. | $40.79 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $40.50 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $37.65 | 2025 | Gemtesa |
| Biogen, INC. | $34.24 | 2021-2025 | Skyclarys |
| Sanofi Pasteur INC. | $33.25 | 2019-2023 | |
| Boston Scientific Corporation | $22.03 | 2025 | Bodyguardian |
| Regeneron Healthcare Solutions, INC. | $21.27 | 2024 | Evkeeza |
| Abiomed | $19.42 | 2024 | Impella |
| Dexcom, INC. | $16.38 | 2023 | Dexcom G6 Transmitter |
| Shire North American Group INC | $16.06 | 2019 | |
| Kaleo, INC. | $15.91 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.53 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $13.06 | 2020 | |
| Aytu Biopharma, INC. | $12.49 | 2019 | |
| Currax Pharmaceuticals LLC | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.